Immunological response to parenteral vaccination with recombinant hepatitis B virus surface antigen virus-like particles expressing Helicobacter pylori KatA epitopes in a murine H. pylori challenge model

Clinical and Vaccine Immunology

Volumn 19, Issue 2, 2012, Pages 268-276

  Kotiw, Michael ^a   Johnson, Megan ^a   Pandey, Manisha ^b   Fry, Scott ^c   Hazell, Stuart L ^a   Netter, Hans J ^d   Good, Michael F ^b   Olive, Colleen ^e  

^a UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; BACTERIAL PROTEIN; EPITOPE; HEPATITIS B SURFACE ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; KATA PROTEIN; RECOMBINANT HEPATITIS B VIRUS SURFACE ANTIGEN HELICOBACTER PYLORI KATA FUSION PROTEIN VIRUS LIKE PARTICLE VACCINE; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GENE; CARBOXY TERMINAL SEQUENCE; COLONY FORMING UNIT; CONTROLLED STUDY; EXPERIMENTAL INFECTION; FEMALE; GENE INSERTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMORAL IMMUNITY; IMMUNIZATION; KATA GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; STOMACH MUCOSA; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL LOAD; BACTERIAL PROTEINS; BACTERIAL VACCINES; CATALASE; EPITOPES; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; VACCINATION; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE; VIRAL FUSION PROTEINS;

EID: 84863404365     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05295-11     Document Type: Article

References (64)

1. Abimiku AG, Dolby JM. 1988. Cross-protection of infant mice against intestinal colonisation by Campylobacter jejuni: importance of heat-labile serotyping (Lior) antigens. J. Med. Microbiol. 26:265-268.
2. Ada GF. 1990. The immunological basis of vaccine development. Semin. Virol. 1:3-11.
3. Akhiani AA, Lycke N. 2002. T cell involvement in experimental Helicobacter pylori specific protective immunity. Recent Res. Dev. Immunol. 4:259.
4. Arora S, Czinn SJ. 2005. Vaccination as a method of preventing H. pylori-associated gastric cancer. Cancer Epidemiol. Biomarkers Prev. 14:1890-1891. (Pubitemid 41161195)
5. Chan K, et al. 2002. Eradication of and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 359:9-13.
6. Cheong WS, Resinger J, Turner SJ, Boyd R, Netter HJ. 2009. Chimeric virus-like particles for delivery of an inserted conserved influenza A-specific CTL epitope. Antiviral Res. 81:113-122.
7. Crabtree JE, Shallcross TM, Heatley RV, Wyatt JI. 1991. Mucosal tumour necrosis factor alpha and interleukin 6 in patients with Helicobacter pylori-associated gastritis. Gut 32:1473-1477.
8. Del Giudice GA, Covacci A, Telford JL, Montecucco C, Rapuolli R. 2001. The design of vaccines against Helicobacter pylori and their development. Annu. Rev. Immunol. 19:523-563. (Pubitemid 32368045)
9. Delpeyroux F, et al. 1987. Insertions in the hepatitis B surface antigen: effect on assembly and secretion of 22nm particles from mammalian cells. J. Mol. Biol. 195:343-350. (Pubitemid 17106693)
10. Delpeyroux F, van Wezel E, Blondel B, Crainic R. 1990. Structural factors modulate the activity of antigenic poliovirus sequences expressed on hybrid hepatitis B surface antigen particles. J. Virol. 64:6090-6100.
11. Dunn BE, Cohen H, Blaser MJ. 1997. Helicobacter pylori. Clin. Microbiol. Rev. 10:720-741. (Pubitemid 27477732)
12. Eck M, et al. 2000. CXC chemokines Groα/IL-8 and IP-10/MIG in Helicobacter pylori gastritis. Clin. Exp. Immunol. 122:192-199.
13. Egan BJ, Katicic M, O'Connor HJ. 2007. Treatment of Helicobacter pylori. Helicobacter 12:31-37. (Pubitemid 47312378)
14. El-Omar EM, et al. 2000. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404:398-402. (Pubitemid 30164342)
15. El-Omar EM. 2001. The importance of interleukin 1β Helicobacter pylori associated disease. Gut 48:743-747. (Pubitemid 32476967)
16. Ermak TH, et al. 1998. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J. Exp. Med. 188:2277-2288. (Pubitemid 29028500)
17. Fox JG, et al. 2000. Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces helicobacter-induced gastric atrophy. Nat. Med. 6:536 -542.
18. Garhart CA, Nedrud JG, Heinzel FP, Sigmund NE, Czinn SJ. 2003. Vaccine-induced protection against Helicobacter pylori in mice lacking both antibodies and interleukin-4. Infect. Immun. 71:3628-3633. (Pubitemid 36637595)
19. Gidding HF, et al. 2007. The impact of a new universal infant and school-based adolescent hepatitis B vaccination program in Australia. Vaccine 25:8637-8641. (Pubitemid 350199587)
20. Gilbert RJC, et al. 2005. Hepatitis B small surface antigen particles are octahedral. Proc. Natl. Acad. Sci. U. S. A. 102:14783-14788. (Pubitemid 41457133)
21. Gorrell RJ, Robbins-Browne RM. 2009. Antibody mediated protection against infection with Helicobacter pylori in a suckling mouse model of passive immunity. Infect. Immun. 77:5116-5129.
22. Guy B, et al. 1998. Systemic immunization with urease protects mice against Helicobacter pylori infection. Vaccine 16:850-856. (Pubitemid 28238673)
23. Harris AG, Hinds FE, Beckhouse AG, Kolesnikow T, Hazell SL. 2002. Resistance to hydrogen peroxide in Helicobacter pylori: role of catalase (KatA) and Fur, and functional analysis of a novel gene product designated 'KatA-associated protein', KapA (HP0874). Microbiol. 148:3813-3825. (Pubitemid 36097443)
24. Harris AG, et al. 2003. Catalase (KatA) and KatA-associated protein (KapA) are essential to persistent colonization in the Helicobacter pylori SS1 mouse model. Microbiology 149:665-672. (Pubitemid 36395101)
25. Janulaityte-Gunther D, et al. 2005. The humoral immune response to Helicobacter pylori infection in children with gastrointestinal symptoms. FEMS Immunol. Med. Microbiol. 44:205-212. (Pubitemid 41373378)
26. Jilg W, et al. 1984. Clinical evaluation of a recombinant hepatitis vaccine. Lancet 11:1174-1175. (Pubitemid 15217671)
27. Jones CD, et al. 1998. Characterization of the T- and B-cell immune response to a new recombinant pre-S1, pre-S2 and SHBs antigen containing hepatitis B vaccine; evidence for superior anti-SHBs antibody induction in responder mice. J. Viral Hepat. 5:5-8.
28. Knoll A, Hottentrager B, Kainz J, Bretschneider B, Jilg W. 2000. Immunogenicity of a combined hepatitisAand B vaccine in healthy young adults. Vaccine 18:2029-2032. (Pubitemid 30114347)
29. Krakowka S, Eaton KA. 2002. Helicobacter pylori-specific immunoglobulin synthesis in gnotobiotic piglets: evidence for induction of mucosal immunity in the stomach. Vet. Immunol. Immunopathol. 88:173-182. (Pubitemid 34786758)
30. Kusters JG, van Vliet AHM, Kuipers EJ. 2006. Pathogenesis of Helicobacter pylori infection. Clin. Microbiol. Rev. 19:449-490. (Pubitemid 44134306)
31. Kwon DH, et al. 2000. Analysis of rdxA and involvement of additional genes encoding NAD(P)H flavin oxidoreductase (FrxA) and ferredoxinlike protein (FdxB) in metronidazole resistance of Helicobacter pylori. Antimicrob. Agents Chemother. 44:2133-2142.
32. Lindholm C, Quiding-Järbrink M, Lönroth H, Svennerholm AM. 2001. Induction of chemokine and cytokine responses by Helicobacter pylori in human stomach explants. Scand. J. Gastroenterol. 36:1022-1029.
33. Maeda S, et al. 2001. Distinct mechanism of Helicobacter pylori-mediated NF-κB activation between gastric cancer cells and monocytic cells. J. Biol. Chem. 276:44856-44864.
34. Malaty HM. 2007. Epidemiology of Helicobacter pylori infection. Best Pract. Res. Clin. Gastroenterol. 21:205-214. (Pubitemid 46421909)
35. Mégraud F. 2004. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53:1374-1384. (Pubitemid 39120130)
36. Michel M, et al. 2007. Optimisation of secretion of recombinant HBsAg virus-like particles: impact on the development of HBV-1/HBV bivalent vaccines. Vaccine 25:1901-1919.
37. Mitchell HM, et al. 1998. A low rate of reinfection following effective therapy against Helicobacter pylori in a developing nation (China). Gastroenterology 114:256-261. (Pubitemid 28093531)
38. Murakami K, et al. 2003. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment. Pharmacol. Ther. 17:119-123. (Pubitemid 36140441)
39. Netter HJ, Macnaughton TB, Woo W-P, Tindle R, Gowans EJ. 2001. Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J. Virol. 75:2130-2141. (Pubitemid 32147552)
40. Netter HJ, Woo W-P, Tindle R, Macfarlan RI, Gowans EJ. 2003. Immunogenicity of recombinant HBsAg/HCV particles in mice preimmunised with hepatitis B virus-specific vaccine. Vaccine 21:2692-2697. (Pubitemid 36703178)
41. Nyström J, et al. 2008. Improved cell mediated immune responses after successful re-vaccination of non-responders to the hepatitis B virus surface antigen (HBsAg) vaccine using the combined hepatitis A and B vaccine. Vaccine 26:5967-5972.
42. Odenbreit S, Wieland B, Haas R. 1996. Cloning and genetic characterization of Helicobacter pylori catalase and construction of a catalase-deficient mutant strain. J. Bacteriol. 178:6960-6967. (Pubitemid 26404975)
43. Osato MS, et al. 2001. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch. Intern. Med. 161:1217-1220. (Pubitemid 32691518)
44. Perez-Perez GI, Rothenbacher D, Brenner H. 2004. Epidemiology of Helicobacter pylori infection. Helicobacter 9:1-6. (Pubitemid 39274100)
45. Petrovsky N, Aguilar J. 2004. Vaccine adjuvants: current state and future trends. Immunol. Cell Biol. 82:488-496. (Pubitemid 39421058)
46. Petrovsky N. 2006. Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine 24:s2/26-s2/29.
47. Radcliff FJ, Hazell SL, Kolesnikow T, Doidge C, Lee A. 1997. Catalase, a novel antigen for Helicobacter pylori vaccination. Infect. Immun. 65:4668-4674. (Pubitemid 27463240)
48. Ren Z, et al. 2000. Circulating T-cell response to Helicobacter pylori infection in chronic gastritis. Helicobacter 5:135-141.
49. Roper RL, Conrad DH, Brown DM, Warner GL, Phipps RP. 1990. Prostaglandin E2 promotes IL-4-induced IgE and IgG1 synthesis. J. Immunol. 145:2644-2651. (Pubitemid 20374591)
50. Schirmbeck R, Böhm W, Reimann J. 1996. Virus-like particles induce MHC class I-restricted T-cell responses. Intervirology 39:111-119. (Pubitemid 26390702)
51. Schormann W, Kraft A, Ponsel D, Bruss V. 2006. Hepatitis B virus-like particle formation in the absence of pregenomic RNA and reverse transcriptase. J. Virol. 80:4187-4190.
52. Schumacher T, et al. 2007. Advanced antigen delivery of murine surviving: chimeric virus-like particles in cancer vaccine research. Int. J. Biomed. Sci. 3:199-205.
53. Shapira SK, et al. 1991. Deletional switch recombination occurs in interleukin-4-induced isotype switching to IgE expression by human B cells. Proc. Natl. Acad. Sci. U. S. A. 88:7528-7532. (Pubitemid 21915186)
54. Smythies LE, et al. 2000. Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-γ, gene-deficient Mice. J. Immunol. 165:1022-1029. (Pubitemid 30484772)
55. Suzuki T, et al. 2002. Localization of antigen-presenting cells in Helicobacter pylori-infected gastric mucosa. Pathol. Int. 52:265-271. (Pubitemid 34587811)
56. Taylor JM, et al. 2006. Helicobacter pylori lipopolysaccharide promotes a Th1 type immune response in immunized mice. Vaccine 24:4987-4994. (Pubitemid 43782682)
57. Thomas LD, et al. 2000. Catalase immunization from Pseudomonas aeruginosa enhances bacterial clearance in the rat lung. Vaccine 19:348-357. (Pubitemid 30621529)
58. Todoroki I, et al. 2000. Suppressive effects of DNA vaccines encoding heat shock protein on Helicobacter pylori-induced gastritis in mice. Biochem. Biophys. Res. Commun. 277:159-163.
59. Tritto E, Mosca F, De Gregorio E. 2009. Mechanisms of action of licenced vaccine adjuvants. Vaccine 27:3331-3334.
60. Ulrich R, Nassal M, Meisel H, Kruger DH. 1998. Core particles of hepatitis B virus as carrier for foreign epitopes. Adv. Virus Res. 50:141-182.
61. Vietheer PTK, Boo I, Drummer HE, Netter HJ. 2007. Immunisations with chimeric hepatitis B virus-like particles (VLPs) to induce potential anti-hepatitis C virus (HCV) neutralizing antibodies. Antivir. Ther. 12:477-487. (Pubitemid 47041146)
62. Weltzin R, Guy B, Thomas WD, Giannasca PJ, Monath TP. 2000. Parenteral adjuvant activities of Escherichia coli heat labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection. Infect. Immun. 68:2775-2782. (Pubitemid 30253855)
63. Whary MT, et al. 2005. Intestinal helminthiasis in Colombian children promotes a Th2 response to Helicobacter pylori: possible implications for gastric carcinogenesis. Cancer Epidemiol. Biomarkers Prev. 14:1464-1469. (Pubitemid 40807347)
64. Woo W-P, Doan T, Herd KA, Netter HJ, Tindle RW. 2006. Hepatitis B surface antigen (HBsAg) vector delivers protective CTL responses to disease-relevant foreign epitopes. J. Virol. 80:3975-3984.